Literature DB >> 23719852

Evaluation of colistin susceptibility in multidrug-resistant clinical isolates from cystic fibrosis, France.

S Biswas1, J-C Dubus, M Reynaud-Gaubert, N Stremler, J-M Rolain.   

Abstract

The emergence of multidrug-resistant (MDR) bacteria in cystic fibrosis (CF) patients has led to the use of colistin drug and the emergence of colistin-resistant Gram-negative bacteria. The aim of this study was to compare the disk diffusion and Etest methods for colistin susceptibility testing on MDR bacteria associated with CF from Marseille, France. Forty-nine MDR clinical isolates (27 Stenotrophomonas maltophilia, 22 Achromobacter xylosoxidans) were used in this study. Disk diffusion and Etest assays were used to assess the reliability of these two techniques. For S. maltophilia, 25 out of 27 isolates had low minimum inhibitory concentrations (MICs, 0.125-0.75 mg/L), whereas two isolates displayed high MICs (32 mg/L). Similarly, 19 out of 22 A. xylosoxidans isolates had low MICs (0.75-3.0 mg/L), whereas three isolates had high MICs (32-256 mg/L). The diameters of zone inhibition with a 50-μg colistin disk displayed a good correlation with the MICs obtained by the Etest. Susceptible and resistant strains were eventually separated using a disk diffusion assay at a cut-off of ≤ 12 mm for a 50-μg disk. Colistin displayed excellent activity against S. maltophilia and A. xylosoxidans and the disk diffusion assay could be confidently used to determine the susceptibility to colistin for MDR Gram-negative bacteria in the context of CF.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23719852     DOI: 10.1007/s10096-013-1898-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  24 in total

1.  BSAC standardized disc susceptibility testing method.

Authors:  J M Andrews
Journal:  J Antimicrob Chemother       Date:  2001-07       Impact factor: 5.790

Review 2.  Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis.

Authors:  Melissa B Miller; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

3.  Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  A S Levin; A A Barone; J Penço; M V Santos; I S Marinho; E A Arruda; E I Manrique; S F Costa
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

Review 4.  Cystic fibrosis.

Authors:  B J Rosenstein; P L Zeitlin
Journal:  Lancet       Date:  1998-01-24       Impact factor: 79.321

5.  Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing.

Authors:  Dolunay Gülmez; Aslı Cakar; Burçin Sener; Jale Karakaya; Gülşen Hasçelik
Journal:  J Infect Chemother       Date:  2010-05-07       Impact factor: 2.211

6.  Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.

Authors:  Samuel M Moskowitz; Elizabeth Garber; Yunhua Chen; Sarah A Clock; Setareh Tabibi; Amanda K Miller; Michael Doctor; Lisa Saiman
Journal:  J Antimicrob Chemother       Date:  2010-04-29       Impact factor: 5.790

7.  Stenotrophomonas maltophilia in cystic fibrosis: improved detection by the use of selective agar and evaluation of antimicrobial resistance.

Authors:  P Goncalves-Vidigal; J Grosse-Onnebrink; U Mellies; J Buer; P-M Rath; J Steinmann
Journal:  J Cyst Fibros       Date:  2011-07-16       Impact factor: 5.482

8.  Stenotrophomonas maltophilia in cystic fibrosis patients.

Authors:  S Ballestero; I Vírseda; H Escobar; L Suárez; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-08       Impact factor: 3.267

9.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

Review 10.  The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia.

Authors:  R C Spencer
Journal:  J Hosp Infect       Date:  1995-06       Impact factor: 3.926

View more
  5 in total

1.  Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia.

Authors:  J W Betts; L M Phee; N Woodford; D W Wareham
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-30       Impact factor: 3.267

2.  Impact of High Diversity of Achromobacter Populations within Cystic Fibrosis Sputum Samples on Antimicrobial Susceptibility Testing.

Authors:  Chloé Dupont; Estelle Jumas-Bilak; Anne-Laure Michon; Raphaël Chiron; Hélène Marchandin
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

3.  Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients.

Authors:  Sean K Tom; Yvonne C W Yau; Trevor Beaudoin; John J LiPuma; Valerie Waters
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

4.  Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary.

Authors:  Emese Juhász; Gergely Krizsán; György Lengyel; Gábor Grósz; Júlia Pongrácz; Katalin Kristóf
Journal:  Ann Clin Microbiol Antimicrob       Date:  2014-12-31       Impact factor: 3.944

Review 5.  Infections in patients with cystic fibrosis: diagnostic microbiology update.

Authors:  Peter H Gilligan
Journal:  Clin Lab Med       Date:  2014-04-12       Impact factor: 1.935

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.